Cargando…
The use of antidementia therapy in non-dementia cognitive disorders associated with COVID-19
INTRODUCTION: The new coronavirus infection causes severe damage to the human body. One of the most serious complication is cognitive impairment. According to a meta-analysis by Maxime Taquet et al. (2021), which assessed neurological and psychiatric outcomes among 236,379 patients diagnosed with CO...
Autores principales: | Liubov, P., Iashina, I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479055/ http://dx.doi.org/10.1192/j.eurpsy.2023.1704 |
Ejemplares similares
-
Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use
por: Wübbeler, Markus, et al.
Publicado: (2015) -
The impact of Medicare prescription drug coverage on the use of antidementia drugs
por: Fowler, Nicole R, et al.
Publicado: (2013) -
Antidementia drug use in Japan: Bridging the research‐to‐practice gap
por: Okumura, Yasuyuki, et al.
Publicado: (2018) -
Association between antidementia medication use and mortality in people diagnosed with dementia with Lewy bodies in the UK: A retrospective cohort study
por: Chen, Shanquan, et al.
Publicado: (2022) -
Are antidementia drugs associated with reduced mortality after a hospital emergency admission in the population with dementia aged 65 years and older?
por: Hapca, Simona, et al.
Publicado: (2019)